Quizantinil Intermediate
have 0 Relevant products
Quizantinil (Ac220), A Small Molecule Receptor Tyrosine Kinase Inhibitor, Is Currently Being Developed By Ambit Biosciences For The Treatment Of Acute Myeloid Leukemia. Its Molecular Target Is Flt3, Also Known As Cd135, Which Is A Proto-Oncogene.
